Cytochrome P450

Introduction
Cytochromes P450 ( 'CYP' ) are enzymes of the  cytochrome family, ie  enzymes originally discovered as cellular pigment] pigments (hence the name <! - reference -> <! - end of reference -> ), which contain porphyrin with an iron atom as the central atom with coordination number 6 (unlike  hemoglobin ), which transitions between states Fe 2+ / Fe 3+ < / sup> performs electron transfer and thus oxidation-reduction reactions

(often monooxygenation). It is involved in both the metabolism of some endogenous metabolites and the biotransformation of most xenobiotics. Human genome contains 57 cytochrome P450 genes, the organism expresses about 100 isoforms , mostly in the liver.

They catalyze the reaction $$ \ mathrm {RH} + \ mathrm {O} _2 + 2 \ mathrm {H} ^ {+} + 2 e ^ {-} \ rightleftharpoons \ mathrm {ROH} + \ mathrm {H} _2 \ mathrm {O} $$ for which they use cytochrome P450 reductase-mediated cofactor NADPH as a source of electrons.

Families 1, 2 and 3 of cytochrome P450 are mainly involved in the metabolism of xenobiotics, while families 4-51 are mainly involved in the metabolism of endogenous substances such as sterols, steroids,  bile acids and fatty acids.

Polymorphism
 'Cytochromes P450'  show an unusual polymorphism. Several situations can occur in a population for a given gene encoding enzyme of the cytochrome P450 family :
 * alleles carry copies of the gene, so there are more than two copies on both alleles & ndash;  ultarapid metabolizer , risk of adverse drug reactions to the metabolite, lack of response to drug
 * increased gene expression & ndash;  Ultrarapid Metabolizer , same as the previous case
 * there is one active gene on each allele & ndash;  extensive metabolizer , normal condition
 * one defective allele & ndash;  intermediate metabolizer , increased drug concentration, decreased metabolite production
 * both partially defective alleles & ndash;  intermediate metabolizer , same as the previous case
 * both alleles completely defective & ndash;  poor metabolizer , very high drug concentration, risk of adverse drug reactions

Slowing down metabolism
If two different drugs are metabolised by cytochrome P450 and thus  competitively  or  inhibit  each other, their concomitant use may exceed the level they would have if they were taken separately. This is particularly important for drugs with a low therapeutic index.

Acceleration of metabolism
It is also often the case that one of the drugs increases the expression of cytochrome P450, so that the other is then metabolised and its concentration decreases. This has been observed, for example, with the concomitant use of some antibiotics and hormonal contraception. In addition, if the metabolic product is a toxic substance, adverse reactions may occur.

Substances that increase CYP expression include, for example, environmental pollutants such as cyclic aromatic hydrocarbons and  polychlorinated biphenyls.

It also depends on possible liver diseases and other influences.

Source

 * ws:Criglerův-Najjarův syndrom

Related Articles

 * Biotransformation

Used literature
See references

